PMID- 37409024
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 14
DP  - 2023
TI  - Clinical efficacy and safety of rimegepant in the treatment of migraine: a 
      meta-analysis of randomized controlled trials.
PG  - 1205778
LID - 10.3389/fneur.2023.1205778 [doi]
LID - 1205778
AB  - BACKGROUND: This study aims to evaluate the clinical efficacy and safety of 
      rimegepant for the treatment of migraine in adult patients using a meta-analysis. 
      METHODS: The PubMed, EMBASE, and Cochrane Library were searched up to March 2022. 
      Only randomized controlled trials (RCTs) that evaluated migraine and other 
      comparator treatments in adult patients were included. The clinical response at 
      the post-treatment evaluation, including acute pain free and relief effect, 
      whereas the secondary outcomes were the risk of adverse events (AEs). RESULTS: A 
      total of 4 RCTs involving 4,230 patients with episodic migraine were included. 
      Outcome indicators for the number of pain free and relief patients at 2 h, 2-24 
      h, 2-48 h post-dose showed that rimegepant had better effects relative to the 
      placebo [free at 2 h: OR = 1.84, 95% CI (1.55, 2.18), P < 0.00001; relief at 2 h: 
      OR = 1.80, 95% CI (1.59, 2.04), P < 0.00001]. And there was no significant 
      difference between the occurrence of adverse events in the experimental and 
      control groups [OR = 1.29, 95% CI (0.99, 1.67), P = 0.06]. CONCLUSION: Rimegepant 
      has better therapeutic effects compared to placebo and no significant difference 
      in adverse events.
CI  - Copyright (c) 2023 Wang, Wang, Zhu and Lin.
FAU - Wang, Qinghui
AU  - Wang Q
AD  - Department of Pharmacy, Chengdu Jinniu District People's Hospital, Chengdu, 
      Sichuan, China.
FAU - Wang, Shuangmei
AU  - Wang S
AD  - Department of Pharmacy, Chengdu Jinniu District People's Hospital, Chengdu, 
      Sichuan, China.
FAU - Zhu, Yi
AU  - Zhu Y
AD  - Department of Pharmacy, Chengdu Jinniu District People's Hospital, Chengdu, 
      Sichuan, China.
FAU - Lin, Fei
AU  - Lin F
AD  - Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, Sichuan, China.
LA  - eng
PT  - Systematic Review
DEP - 20230620
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC10318539
OTO - NOTNLM
OT  - efficacy
OT  - meta-analysis
OT  - migraine
OT  - rimegepant
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/07/06 06:42
MHDA- 2023/07/06 06:43
PMCR- 2023/06/20
CRDT- 2023/07/06 04:18
PHST- 2023/04/19 00:00 [received]
PHST- 2023/06/06 00:00 [accepted]
PHST- 2023/07/06 06:43 [medline]
PHST- 2023/07/06 06:42 [pubmed]
PHST- 2023/07/06 04:18 [entrez]
PHST- 2023/06/20 00:00 [pmc-release]
AID - 10.3389/fneur.2023.1205778 [doi]
PST - epublish
SO  - Front Neurol. 2023 Jun 20;14:1205778. doi: 10.3389/fneur.2023.1205778. 
      eCollection 2023.